Abstract
Background: Data concerning phenotypes in bronchiectasis are scarce. Objective: The aim of this study was to describe the clinical, functional and microbiological phenotypes of patients with bronchiectasis. Methods: A monocentric retrospective study in a university hospital in France was conducted over 10 years (2002-2012). Non-cystic fibrosis patients with tomographic confirmation of bronchiectasis were included. The clinical, functional and microbiological data of patients were analyzed relying on the underlying etiology. Results: Of the311 included patients, an etiology was found for 245 of them. At the time of diagnosis, the median age was 61 years and the mean FEV1 was 63% of predicted. The main causes of bronchiectasis were post-infectious (50%, mostly related to tuberculosis), chronic obstructive pulmonary disease (COPD; 13%) and idiopathic (11%). Other causes were immune deficiency (6%), asthma (4%), autoimmunity (3%), tumor (2%) and other causes (4%). The comparison of phenotypic traits shows significant differences between COPD, congenital and idiopathic groups in term of sex (p = 0.0175), tobacco status (p < 0.0001), FEV1 (p = 0.0412) and age at diagnosis (p < 0.001), Pseudomonas aeruginosa (PA) colonization (p = 0.0276) and lobectomy (0.0093). Functional follow-up was available in 30% of patients with a median duration of 2.7 years. Presence of PA was associated with a lower median FEV1 at diagnosis (43% p < 0.003) but not with a faster rate of decline in FEV1. Conclusion: Distinctive clinical, functional and microbiological features were found for idiopathic, congenital and COPD-related bronchiectasis. A prospective follow-up of these subgroups is necessary to validate their relevance in the management of bacterial colonization and specific complications of these bronchiectases.
Journal Section:
Editor's choice
References
1.
Cole PJ: Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
[PubMed]
2.
Chalmers JD, Aliberti S, Blasi F: Management of bronchiectasis in adults. Eur Respir J 2015;45:1446-1462.
[PubMed]
3.
Bronchiectasis Research Registry. COPD Foundation. http://www.copdfoundation.org/Research/Bronchiectasis-Research-Registry/Learn-More.aspx (accessed September 23, 2015).
4.
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al: The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-585.
[PubMed]
5.
Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM: CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. Am J Roentgenol 1995;165:261-267.
[PubMed]
6.
Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD: Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996;51:914-918.
[PubMed]
7.
Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA: Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9:1601-1604.
[PubMed]
8.
Swinson DR, Symmons D, Suresh U, Jones M, Booth J: Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36:689-691.
[PubMed]
9.
Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R: Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536-541.
[PubMed]
10.
Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, et al: Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998;12:820-824.
[PubMed]
11.
Cartier Y, Kavanagh PV, Johkoh T, Mason AC, Müller NL: Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases. AJR Am J Roentgenol 1999;173:47-52.
[PubMed]
12.
Lynch DA, Newell J, Hale V, Dyer D, Corkery K, Fox NL, et al: Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol 1999;173:53-58.
[PubMed]
13.
Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al: An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-1284.
[PubMed]
14.
Sheehan RE, Wells AU, Copley SJ, Desai SR, Howling SJ, Cole PJ, et al: A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002;20:581-587.
[PubMed]
15.
Ooi GC, Khong PL, Chan-Yeung M, Ho JCM, Chan PKS, Lee JCK, et al: High-resolution CT quantification of bronchiectasis: clinical and functional correlation. Radiology 2002;225:663-672.
[PubMed]
16.
Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al: Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57:15-19.
[PubMed]
17.
Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ, et al: Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000;55:198-204.
[PubMed]
18.
Patel IS, Vlahos I, Wilkinson TMA, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al: Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-407.
[PubMed]
19.
Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ: Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-745.
[PubMed]
20.
Davies G, Wells AU, Doffman S, Watanabe S, Wilson R: The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28:974-979.
[PubMed]
21.
Wickremasinghe M, Ozerovitch LJ, Davies G, Wodehouse T, Chadwick MV, Abdallah S, et al: Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005;60:1045-1051.
[PubMed]
22.
Martínez-García MA, Soler-Cataluña J-J, Perpiñá-Tordera M, Román-Sánchez P, Soriano J: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-1572.
[PubMed]
23.
Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, et al: Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101:1390-1397.
[PubMed]
24.
Shoemark A, Ozerovitch L, Wilson R: Aetiology in adult patients with bronchiectasis. Respir Med 2007;101:1163-1170.
[PubMed]
25.
Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al: Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-849.
[PubMed]
26.
Murray MP, Pentland JL, Turnbull K, MacQuarrie S, Hill AT: Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:361-364.
[PubMed]
27.
Finklea JD, Khan G, Thomas S, Song J, Myers D, Arroliga AC: Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010;104:816-821.
[PubMed]
28.
Kwak HJ, Moon J-Y, Choi YW, Kim TH, Sohn JW, Yoon HJ, et al: High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010;222:237-242.
[PubMed]
29.
McShane PJ, Naureckas ET, Strek ME: Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012;142:159-167.
[PubMed]
30.
Martínez-García M-A, de la Rosa Carrillo D, Soler-Cataluña J-J, Donat-Sanz Y, Serra PC, Lerma MA, et al: Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:823-831.
[PubMed]
31.
Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013;107:1001-1007.
[PubMed]
32.
Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ: Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108:287-296.
[PubMed]
33.
Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S, Mijakoski D: Assessment of the non-cystic fibrosis bronchiectasis severity: the FACED Score vs the Bronchiectasis Severity Index. Open Respir Med J 2015;9:46-51.
[PubMed]
34.
Habesoglu MA, Ugurlu AO, Eyuboglu FO: Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Ann Thorac Med 2011;6:131-136.
[PubMed]
35.
Qi Q, Li T, Li JC, Li Y: Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis. Braz J Med Biol Res 2015;48:715-724.
[PubMed]
36.
Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ: Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:21.
[PubMed]
37.
Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón R-M, Máiz Carro L, de la Rosa Carrillo D, et al: Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-1367.
[PubMed]
38.
Keistinen T, Säynäjäkangas O, Tuuponen T, Kivelä SL: Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997;10:2784-2787.
[PubMed]
39.
Seitz AE: Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010;138:944.
[PubMed]
40.
Gaudelus J, De Pontual L: Epidemiology of tuberculosis in France (in French). Arch Pediatr 2005;12:S83-S87.
[PubMed]
41.
Novosad SA, Barker AF: Chronic obstructive pulmonary disease and bronchiectasis: Curr Opin Pulm Med 2013;19:133-139.
[PubMed]
42.
Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al: Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016;47:113--122.
[PubMed]
43.
Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group: British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
[PubMed]
44.
EMBARC. https://www.bronchiectasis.eu/ (accessed September 23, 2015).
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
